Solid Biosciences (SLDB) Income from Non-Controlling Interests (2017)
Solid Biosciences (SLDB) reported Income from Non-Controlling Interests of -$1.1 million for Q1 2017.
Solid Biosciences (SLDB) Income from Non-Controlling Interests (2017) Analysis & Trends
Solid Biosciences (SLDB) has 1 years of Income from Non-Controlling Interests data on file, last reported at -$1.1 million in Q1 2017.
- For the quarter ending Q1 2017, Income from Non-Controlling Interests changed N/A year-over-year to -$1.1 million; the trailing twelve-month figure through Dec 2017 stood at -$1.1 million (changed N/A YoY), and the FY2017 full-year result was -$1.1 million, up 52.55% from the prior year.
- Income from Non-Controlling Interests steadied at -$1.1 million in Q1 2017.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$1.1 million in Q1 2017 to a low of -$1.1 million in Q1 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Solid Biosciences | 871.35 Mn | 871.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | -1.06 Mn |